Oral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: a nested case–control study
نویسندگان
چکیده
OBJECTIVES To evaluate the association between the long-term use of bisphosphonates and the risk of hip fracture compared to never use among women aged 65 years or older. DESIGN Case-control study nested in a cohort. SETTING General practice research database operated by the Spanish Medicines Agency. PARTICIPANTS Cases of hip fracture were defined as women aged 65 years or older with a validated first diagnosis of hip fracture between 2005 and 2008. Five controls free of hip fracture were matched on age and calendar-year with each case. INTERVENTIONS Information on bisphosphonate use, hip fractures, comedication and comorbidities was collected. PRIMARY OUTCOMES Hip fracture risk comparing bisphosphonate users versus never users. SECONDARY OUTCOMES Hip fracture risk comparing bisphosphonate users versus never users by individual drugs. RESULTS The study included 2009 incident hip fractures and 10 045 matched controls. Hip-fracture risk did not differ between bisphosphonate users and never users, adjusted OR=1.09 (95% CI 0.94 to 1.27). No association was observed between hip fracture risk and cumulative duration of bisphosphonate treatment. However, when treatment duration is analysed as time since first prescription, hip fracture risks of the different subgroups compared to never users obtained were as follows: <1 year, OR 0.85 (95% CI 0.60 to 1.21); 1 to <3 years, OR 1.02 (95% CI 0.82 to 1.26); ≥3 years, OR 1.32 (95% CI 1.05 to 1.65) (p for trend=0.03). CONCLUSIONS Ever use of oral bisphosphonates was not associated with a decreased risk of hip fracture in women aged 65 or older as compared to never use. No association was observed between hip fracture risk and cumulative duration of bisphosphonate treatment. However, when treatment duration is analysed as time since first prescription, a statistically significant increased risk for hip fracture was observed in patients exposed to bisphosphonates over 3 years. TRIAL REGISTRATION Spanish Ministry of Health. TRA-071.
منابع مشابه
Economic Analysis of Bisphosphonate Use after Distal Radius Fracture for Prevention of Hip Fracture
Background: Osteoporosis is a common condition among the elderly population, and is associated with an increased risk of fracture. One of the most common fragility fractures involve the distal radius, and are associated with risk of subsequent fragility fracture. Early treatment with bisphosphonates has been suggested to decrease the population hip fracture burden. However, there have been no p...
متن کاملOral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case–control study
OBJECTIVES To evaluate the association between bisphosphonate use and the risk of atypical femoral fractures among women aged 65 or older. DESIGN Nested case-control study. SETTING General practice research database in Spain. EXPOSURES Use of oral bisphosphonates before the occurrence of atypical fractures among cases or the corresponding index date among controls. Bisphosphonate use was ...
متن کاملAbdominal fat and hip fracture risk in the elderly: The Dubbo Osteoporosis Epidemiology Study
BACKGROUND Fat mass, which is a major component of body weight, is directly related to bone mineral density and reduced fracture risk. It is not known whether abdominal fat is associated with hip fracture. The present study was designed to examine the association between abdominal fat and hip fracture in women and men aged 60+ years. METHODS This was a nested case-control study with one fract...
متن کاملBisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: A meta-analysis
OBJECTIVE This meta-analysis was conducted to investigate the efficacy of bisphosphonates for preventing recurrent hip fracture and reducing the mortality of elderly patient with hip fracture. METHODS The databases of Pubmed, Embase and Cochrane Library were searched. All randomized or prospective matched controlled trials that assessed the efficacy of bisphosphonate for elderly patients with...
متن کامل'Fracture incidence after 3 years of aromatase inhibitor therapy'.
BACKGROUND The purpose of this study was to describe the fracture incidence and bone mineral density (BMD) evolution in a large cohort of post-menopausal women with breast cancer after 3 years of aromatase inhibitor (AI) therapy. PATIENTS AND METHODS A prospective, longitudinal study in real-life setting. Each woman had an extensive medical assessment, a biological evaluation, a BMD measureme...
متن کامل